Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $171 | $165 | $115 | $102 |
| - Cash | $7 | $8 | $6 | $8 |
| + Debt | $50 | $49 | $48 | $47 |
| Enterprise Value | $215 | $206 | $157 | $141 |
| Revenue | $48 | $3 | $4 | $5 |
| % Growth | 1,308.4% | -4.4% | -35.1% | – |
| Gross Profit | $48 | $3 | $4 | $5 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $34 | -$8 | -$7 | -$4 |
| % Margin | 69.9% | -222.7% | -204.5% | -76.5% |
| Net Income | $25 | -$10 | -$9 | -$7 |
| % Margin | 52.9% | -280.5% | -260.3% | -126.5% |
| EPS Diluted | 1.36 | -0.51 | -0.52 | -0.39 |
| % Growth | 366.7% | 1.9% | -33.3% | – |
| Operating Cash Flow | -$9 | -$9 | -$5 | -$6 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$9 | -$9 | -$5 | -$6 |